Predicting tumour radiosensitivity to deliver precision radiotherapy
Nature Reviews Clinical Oncology, Published online: 07 December 2022; doi:10.1038/s41571-022-00709-yAlthough radiotherapy affects multiple cellular pathways, treatments are generally planned with the assumption that all tumours respond similarly to radiation. The authors of this Review summarize the effect of various pathways activated by radiotherapy on tumour responses to radiotherapy and present the current knowledge on genomic classifiers designed to inform treatment decisions. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 7, 2022 Category: Cancer & Oncology Authors: James M. Price Asmithaa Prabhakaran Catharine M. L. West Source Type: research
New data confirm clinical utility of ctDNA
Nature Reviews Clinical Oncology, Published online: 06 December 2022; doi:10.1038/s41571-022-00716-zNew data confirm clinical utility of ctDNA (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 6, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Criteria for the translation of radiomics into clinically useful tests
Nature Reviews Clinical Oncology, Published online: 28 November 2022; doi:10.1038/s41571-022-00707-0Despite a considerable increase in research output over the past decades, the translation of radiomic research into clinically useful tests has been limited. In this Review, the authors provide 16 key criteria to guide the clinical translation of radiomics with the hope of accelerating the use of this technology to improve patient outcomes. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 28, 2022 Category: Cancer & Oncology Authors: Erich P. Huang James P. B. O ’Connor Lisa M. McShane Maryellen L. Giger Philippe Lambin Paul E. Kinahan Eliot L. Siegel Lalitha K. Shankar Source Type: research
PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching
Nature Reviews Clinical Oncology, Published online: 23 November 2022; doi:10.1038/s41571-022-00712-3PADA-1 is the first trial to demonstrate benefit from a treatment-switching strategy guided by active monitoring of ESR1 mutations in plasma circulating tumour DNA (ctDNA) from patients with breast cancer. The results of this trial raise important questions about the specific treatment approach tested, and the feasibility of trials incorporating longitudinal ctDNA analyses to anticipate resistance and guide treatment. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 23, 2022 Category: Cancer & Oncology Authors: Ben O ’Leary Source Type: research
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Nature Reviews Clinical Oncology, Published online: 23 November 2022; doi:10.1038/s41571-022-00704-3Chimeric antigen receptor (CAR) T cells are effective therapies for patients with relapsed and/or refractory B cell malignancies, partly owing to the ability to target B cell-specific antigens. However, CAR T cells targeting solid tumour antigens are likely to carry a higher risk of on-target, off-tumour toxicity (OTOT). Here, the authors summarize the available data on OTOT in the context of CAR T cells targeting solid tumour antigens and describe novel CAR T cell designs that might overcome such toxicities. (Source: Nature...
Source: Nature Reviews Clinical Oncology - November 23, 2022 Category: Cancer & Oncology Authors: Christian L. Flugel Robbie G. Majzner Giedre Krenciute Gianpietro Dotti Stanley R. Riddell Dimitrios L. Wagner Mohamed Abou-el-Enein Source Type: research
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data
Nature Reviews Clinical Oncology, Published online: 23 November 2022; doi:10.1038/s41571-022-00710-5The first phase III trial to test perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma yielded highly promising results, leading to regulatory approvals of adjuvant pembrolizumab. However, subsequent phase III trials, including the IMmotion010 trial of adjuvant atezolizumab, did not demonstrate similar benefits. Although molecular biomarkers are urgently needed to better delineate responder subgroups, the unique design of each trial might partially explain some of the patterns identified. (Sou...
Source: Nature Reviews Clinical Oncology - November 23, 2022 Category: Cancer & Oncology Authors: Chris Labaki Toni K. Choueiri Source Type: research
Promise with co-administration of CAR T cells
Nature Reviews Clinical Oncology, Published online: 22 November 2022; doi:10.1038/s41571-022-00713-2Promise with co-administration of CAR T cells (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 22, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Brentuximab vedotin improves outcomes
Nature Reviews Clinical Oncology, Published online: 22 November 2022; doi:10.1038/s41571-022-00715-0Brentuximab vedotin improves outcomes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 22, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Barriers in access to oncology drugs — a global crisis
Nature Reviews Clinical Oncology, Published online: 15 November 2022; doi:10.1038/s41571-022-00700-7In the past decade, oncologists worldwide have seen unprecedented advances in drug development and approvals but have also become increasingly cognizant of the rising costs of and increasing inequities in access to these therapies. These trends have resulted in the current problematic situation in which dramatic disparities in outcomes exist among patients with cancer worldwide owing, in part, to the lack of access to drugs that provide clinically meaningful benefits. In this Viewpoint, we have asked six oncologists working ...
Source: Nature Reviews Clinical Oncology - November 15, 2022 Category: Cancer & Oncology Authors: Carlos Barrios Gilberto de Lima Lopes Mastura Md Yusof Fidel Rubagumya Piotr Rutkowski Manju Sengar Source Type: research
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
Nature Reviews Clinical Oncology, Published online: 15 November 2022; doi:10.1038/s41571-022-00711-4CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 15, 2022 Category: Cancer & Oncology Authors: Richard T. Maziarz Jordan Gauthier Source Type: research
DREAMseq of therapy for BRAF-mutant melanoma
Nature Reviews Clinical Oncology, Published online: 09 November 2022; doi:10.1038/s41571-022-00708-zDREAMseq of therapy for BRAF-mutant melanoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 9, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
From WCC 2022
Nature Reviews Clinical Oncology, Published online: 03 November 2022; doi:10.1038/s41571-022-00706-1From WCC 2022 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 3, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Bemarituzumab enters the FIGHT
Nature Reviews Clinical Oncology, Published online: 02 November 2022; doi:10.1038/s41571-022-00705-2Bemarituzumab enters the FIGHT (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 2, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Targeting drugs to tumours using cell membrane-coated nanoparticles
Nature Reviews Clinical Oncology, Published online: 28 October 2022; doi:10.1038/s41571-022-00699-xOwing to several limitations, including elimination by the immune system and a lack of tumour specificity, systemically administered synthetic nanoparticles are used for a limited range of cancer indications. In this Review, the authors describe the potential of cellular nanoparticles (comprising a cell membrane coating around a synthetic core) to overcome these issues as well as their application in drug delivery, phototherapy and immunotherapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 28, 2022 Category: Cancer & Oncology Authors: Ronnie H. Fang Weiwei Gao Liangfang Zhang Source Type: research
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Nature Reviews Clinical Oncology, Published online: 28 October 2022; doi:10.1038/s41571-022-00696-0Neuroendocrine neoplasms (NENs), which can develop in almost any organ and range from indolent neuroendocrine tumours (NETs) to rapidly progressive and fatal neuroendocrine carcinomas (NECs), have historically been approached in a siloed manner according to their specific tissue of origin. However, NETs and NECs across different sites of origin often share genomic and phenotypic characteristics. In this Review, the authors discuss both the clinical and biological commonalities as well as key organ-specific differences of NENs...
Source: Nature Reviews Clinical Oncology - October 28, 2022 Category: Cancer & Oncology Authors: Kenta Kawasaki Natasha Rekhtman Álvaro Quintanal-Villalonga Charles M. Rudin Source Type: research
